Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:NAMS NYSE:QGEN NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$53.33+4.2%$48.97$21.72▼$54.60$10.20B1.252.93 million shs2.16 million shsNAMSNewAmsterdam Pharma$26.73+9.1%$23.91$14.06▼$27.35$3.01B-0.01890,726 shs756,011 shsQGENQiagen$45.75+0.7%$48.33$37.63▼$51.88$10.17B0.641.38 million shs2.19 million shsROIVRoivant Sciences$15.09-1.2%$12.07$8.73▼$16.05$10.30B1.156.08 million shs9.44 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.60%-3.36%+4.41%+27.95%+91.47%NAMSNewAmsterdam Pharma-0.12%-8.96%-3.58%+34.56%+58.51%QGENQiagen-0.35%-1.35%-6.62%-2.36%+2.38%ROIVRoivant Sciences+7.76%+10.97%+29.38%+33.57%+26.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$53.33+4.2%$48.97$21.72▼$54.60$10.20B1.252.93 million shs2.16 million shsNAMSNewAmsterdam Pharma$26.73+9.1%$23.91$14.06▼$27.35$3.01B-0.01890,726 shs756,011 shsQGENQiagen$45.75+0.7%$48.33$37.63▼$51.88$10.17B0.641.38 million shs2.19 million shsROIVRoivant Sciences$15.09-1.2%$12.07$8.73▼$16.05$10.30B1.156.08 million shs9.44 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.60%-3.36%+4.41%+27.95%+91.47%NAMSNewAmsterdam Pharma-0.12%-8.96%-3.58%+34.56%+58.51%QGENQiagen-0.35%-1.35%-6.62%-2.36%+2.38%ROIVRoivant Sciences+7.76%+10.97%+29.38%+33.57%+26.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9419.90% UpsideNAMSNewAmsterdam Pharma 2.90Moderate Buy$41.5555.43% UpsideQGENQiagen 2.27Hold$49.698.60% UpsideROIVRoivant Sciences 2.89Moderate Buy$19.9432.12% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, QGEN, BBIO, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/18/2025ROIVRoivant SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/18/2025ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/18/2025ROIVRoivant SciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $21.009/18/2025ROIVRoivant SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$16.00 ➝ $20.009/18/2025ROIVRoivant SciencesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $16.509/18/2025ROIVRoivant SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $22.009/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $20.009/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M45.94N/AN/A($7.71) per share-6.92NAMSNewAmsterdam Pharma$64.01M47.04N/AN/A$8.20 per share3.26QGENQiagen$1.98B5.14$3.22 per share14.23$16.05 per share2.85ROIVRoivant Sciences$29.05M354.72N/AN/A$7.45 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)QGENQiagen$83.59M$1.6927.0318.602.4118.30%14.77%8.87%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest NAMS, QGEN, BBIO, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AQGENQiagen$0.250.55%N/A14.79%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08NAMSNewAmsterdam PharmaN/A21.0821.08QGENQiagen0.251.611.35ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%NAMSNewAmsterdam Pharma89.89%QGENQiagen70.00%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%NAMSNewAmsterdam Pharma20.84%QGENQiagen9.00%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableNAMSNewAmsterdam Pharma4112.63 million89.16 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableNAMS, QGEN, BBIO, and ROIV HeadlinesRecent News About These CompaniesWhich Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Roivant Sciences Ltd. Stock?September 18 at 12:08 PM | aaii.comARoivant Sciences price target raised to $20 from $18 at JefferiesSeptember 18 at 12:08 PM | msn.comMontes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?September 18 at 11:36 AM | zacks.comRoivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive ResultsSeptember 18 at 11:11 AM | insidermonkey.comRoivant Sciences (NASDAQ:ROIV) Hits New 1-Year High - What's Next?September 18 at 9:56 AM | marketbeat.comRoivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune DiseaseSeptember 17 at 4:53 PM | msn.comRoivant Sciences Ltd. (ROIV) Discusses on Brepocitinib in DM: VALOR Phase 3 Study Results ConferenceSeptember 17 at 4:01 PM | seekingalpha.comRoivant Sciences Ltd. (ROIV) Discusses On Brepocitinib In DM: VALOR Phase 3 Study Results Conference (Transcript)September 17 at 3:43 PM | seekingalpha.comRoivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease TrialSeptember 17 at 12:13 PM | benzinga.comS&P 500 Futures Steady in Premarket Trading; Workday, Roivant Sciences LeadSeptember 17 at 11:52 AM | barrons.comRoivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune DiseaseSeptember 17 at 11:52 AM | msn.comRoivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trialSeptember 17 at 8:21 AM | reuters.comRoivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)September 17 at 7:00 AM | globenewswire.comPeak Financial Advisors LLC Invests $472,000 in Roivant Sciences Ltd. $ROIVSeptember 16 at 5:55 AM | marketbeat.comVivek Ramaswamy Sells $22.7 Million of Roivant Sciences StockSeptember 14, 2025 | msn.comRoivant Sciences Ltd. $ROIV Shares Bought by AmundiSeptember 13, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for MosliciguatSeptember 12, 2025 | finance.yahoo.comRoivant Sciences (ROIV) Announces US$500 Million Share Repurchase Program Amid Recent ChallengesSeptember 12, 2025 | uk.finance.yahoo.comRoivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma ListSeptember 12, 2025 | markets.businessinsider.comRoivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Still a Buy?September 12, 2025 | marketbeat.comTeza Capital Management LLC Buys New Holdings in Roivant Sciences Ltd. $ROIVSeptember 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, QGEN, BBIO, and ROIV Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$53.33 +2.15 (+4.20%) Closing price 04:00 PM EasternExtended Trading$52.77 -0.56 (-1.05%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.NewAmsterdam Pharma NASDAQ:NAMS$26.73 +2.24 (+9.15%) Closing price 04:00 PM EasternExtended Trading$26.66 -0.07 (-0.24%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Qiagen NYSE:QGEN$45.75 +0.33 (+0.73%) Closing price 03:59 PM EasternExtended Trading$45.74 -0.01 (-0.01%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$15.09 -0.19 (-1.24%) Closing price 04:00 PM EasternExtended Trading$15.05 -0.04 (-0.26%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
